The agent successfully assembled a comprehensive explanation of NeuroTint's business, target audience, pricing, and competitive positioning—but had to rely heavily on web search (50% of fetches) because the website itself returned only boilerplate HTML with sparse visible content. Direct fetches of the homepage, products page, and individual product pages yielded minimal actionable text; the agent extracted most of its answer from search snippets and inferred positioning from competitor research rather than from NeuroTint's own published messaging.

• ›Direct website fetches [1, 4, 9, 10, 15] returned only HTML scaffolding with no visible product descriptions, pricing tables, or positioning copy in the response snippets—suggesting dynamic content rendering or truncation. The agent could not answer the task from the site alone.
• ›Web search results [6, 7, 12, 13, 14, 18] provided the core facts: product categories (FL-41, C01, Z1, E-Blue tints), pricing ($249–$299 AUD), and audience (migraine, photosensitivity, epilepsy, achromatopsia). These were cited directly in the final response and sourced from search engine snippets, not from the website's own content.
• ›The agent had to infer clinical positioning (NORA partnership, 'neuro-optometric specialists') from search results about competitors (TheraSpecs, Avulux) and from the company name/tagline visible in search titles, not from an 'About' or 'Our Story' page that returned 200 but yielded no readable text in the fetch.
• ›Pricing information ([14] site-specific search) was found via search indexing, not via an obvious pricing page or product page—indicating the site publishes pricing but does not surface it prominently in the HTML structure the agent could read.
• ›The agent correctly identified gaps (limited product specs, unclear prescription options, sparse clinical evidence, missing delivery timelines) as things it 'couldn't find'—demonstrating awareness that the site's content was incomplete or poorly exposed, not that the agent failed to search.